Private oncology outfit Oncternal uses GTx as shell to make Nasdaq debut

Months after declaring it was exploring strategic options following the failure of its lead experimental drug in a mid-stage study involving patients with stress urinary incontinence, GTx has agreed to be the vehicle that private oncology-focused biotech Oncternal Therapeutics is using to leap onto the Nasdaq.